Compare · MRNA vs TVGN
MRNA vs TVGN
Side-by-side comparison of Moderna Inc. (MRNA) and Tevogen Bio Holdings Inc. (TVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TVGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $94.42B, about 847.5x TVGN ($111.4M).
- Over the past year, MRNA is up 737.1% and TVGN is down 82.5% - MRNA leads by 819.6 points.
- MRNA has been more active in the news (11 items in the past 4 weeks vs 4 for TVGN).
- MRNA has more recent analyst coverage (25 ratings vs 2 for TVGN).
- Company
- Moderna Inc.
- Tevogen Bio Holdings Inc.
- Price
- $217.55-7.99%
- $6.05-20.75%
- Market cap
- $94.42B
- $111.4M
- 1M return
- +37.67%
- -21.36%
- 1Y return
- +737.05%
- -82.53%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2022
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 2
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Latest TVGN
- UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
- Chief Executive Officer Saadi Ryan H. was granted 8,000,000 shares, increasing direct ownership by 216% to 11,705,689 units (SEC Form 4)
- Chief Financial Officer Desai Kirti was granted 750,000 shares, increasing direct ownership by 309% to 992,983 units (SEC Form 4)
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Goh Keow Lin was granted 75,000 shares, increasing direct ownership by 154% to 123,678 units (SEC Form 4)
- Director Podlogar Susan M was granted 75,000 shares, increasing direct ownership by 154% to 123,678 units (SEC Form 4)
- Director Sordillo Victor J. was granted 75,000 shares, increasing direct ownership by 146% to 126,539 units (SEC Form 4)